SI2556071T1 - Kinazni inhibitorji in njihova uporaba pri zdravljenju raka - Google Patents

Kinazni inhibitorji in njihova uporaba pri zdravljenju raka

Info

Publication number
SI2556071T1
SI2556071T1 SI201131015A SI201131015A SI2556071T1 SI 2556071 T1 SI2556071 T1 SI 2556071T1 SI 201131015 A SI201131015 A SI 201131015A SI 201131015 A SI201131015 A SI 201131015A SI 2556071 T1 SI2556071 T1 SI 2556071T1
Authority
SI
Slovenia
Prior art keywords
treating cancer
kinase inhibitors
kinase
inhibitors
cancer
Prior art date
Application number
SI201131015A
Other languages
English (en)
Inventor
Peter Brent Sampson
Yong Liu
Sze-Wan Li
Bryan T. Forrest
Heinz W. Pauls
Louise G. Edwards
Miklos Feher
Narendra Kumar B. Patel
Radoslaw Laufer
Guohua Pan
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2010/000518 external-priority patent/WO2010115279A1/en
Application filed by University Health Network filed Critical University Health Network
Publication of SI2556071T1 publication Critical patent/SI2556071T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
SI201131015A 2010-04-06 2011-04-06 Kinazni inhibitorji in njihova uporaba pri zdravljenju raka SI2556071T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32133210P 2010-04-06 2010-04-06
US32132910P 2010-04-06 2010-04-06
PCT/CA2010/000518 WO2010115279A1 (en) 2009-04-06 2010-04-06 Kinase inhibitors and method of treating cancer with same
EP11764988.9A EP2556071B1 (en) 2010-04-06 2011-04-06 Kinase inhibitors and their use in treating cancer
PCT/CA2011/000386 WO2011123946A1 (en) 2010-04-06 2011-04-06 Kinase inhibitors and method of treating cancer with same

Publications (1)

Publication Number Publication Date
SI2556071T1 true SI2556071T1 (sl) 2016-12-30

Family

ID=44761967

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201131015A SI2556071T1 (sl) 2010-04-06 2011-04-06 Kinazni inhibitorji in njihova uporaba pri zdravljenju raka

Country Status (25)

Country Link
US (9) US8263596B2 (sl)
EP (2) EP2556071B1 (sl)
JP (1) JP5442906B2 (sl)
KR (1) KR101782668B1 (sl)
CN (1) CN102892766B (sl)
AU (1) AU2011238384B2 (sl)
BR (1) BR112012025496B1 (sl)
CY (1) CY1118610T1 (sl)
DK (1) DK2556071T3 (sl)
EA (1) EA023173B1 (sl)
ES (2) ES2603613T3 (sl)
HR (1) HRP20161498T1 (sl)
HU (1) HUE030651T2 (sl)
IL (1) IL221556A (sl)
LT (1) LT2556071T (sl)
ME (1) ME02545B (sl)
MX (1) MX2012011516A (sl)
NZ (1) NZ602350A (sl)
PL (1) PL2556071T3 (sl)
PT (1) PT2556071T (sl)
SG (1) SG183875A1 (sl)
SI (1) SI2556071T1 (sl)
SM (1) SMT201600430B (sl)
TW (1) TWI516262B (sl)
WO (2) WO2011123947A1 (sl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765748B2 (en) * 2007-12-21 2014-07-01 University Health Network Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
ES2465971T3 (es) 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
MX2012011516A (es) 2010-04-06 2013-03-08 Univ Health Network Inhibidores de cinasa, y metodo para tratar el cancer con los mismos.
US8933070B2 (en) 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
CA2880178C (en) * 2012-07-27 2021-10-26 Sato Pharmaceutical Co., Ltd. Difluoromethylene compound
EA030089B1 (ru) 2013-10-18 2018-06-29 Юниверсити Хелс Нетуорк Лечение рака поджелудочной железы
JP6492072B2 (ja) 2013-10-18 2019-03-27 ユニバーシティー ヘルス ネットワーク Ｐｌｋ４阻害剤の塩および結晶形態
CN104130175A (zh) * 2014-06-13 2014-11-05 天津科技大学 不同位置取代吲哚酮类衍生物及其应用
US11608334B2 (en) 2017-02-08 2023-03-21 The National Institutes of Pharmaceutical R&D Co., Ltd. Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof
CN108947961B (zh) * 2017-05-18 2021-06-04 四川大学 吲唑类衍生物及其制备方法和用途
CN111225670A (zh) * 2017-09-08 2020-06-02 大学健康网络 抑制Polo样激酶4的组合疗法
BR112021021106A2 (pt) * 2019-04-24 2021-12-14 Univ Health Network Forma cristalina s4 do inibidor plk4 fumarato (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)-1h-imidazol-6-il)-5'-metoxiespiro[ciclopropano-1,3'-indolin]-2'ona
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
CN112250614B (zh) * 2020-10-20 2022-02-01 苏州大学 3-螺三元环吲哚酮衍生物的合成方法
TW202300485A (zh) * 2021-03-02 2023-01-01 大陸商上海齊魯製藥研究中心有限公司 Plk4抑制劑及其用途
IL308346A (en) 2021-05-11 2024-01-01 Oric Pharmaceuticals Inc POLO-like kinase 4 inhibitors
CN115677682B (zh) * 2021-07-30 2023-07-18 上海齐鲁制药研究中心有限公司 螺环类plk4抑制剂及其用途
US11970494B2 (en) 2021-11-09 2024-04-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2024006379A1 (en) * 2022-06-30 2024-01-04 Axonis Therapeutics, Inc. Methods and compounds for inhibiting mkk7 enzymes

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3310891A1 (de) 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US5182397A (en) * 1990-05-31 1993-01-26 American Cyanamid Company Aryloxyspiroalkylindolinone herbicides
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1998007695A1 (en) 1996-08-23 1998-02-26 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
CA2383623A1 (en) 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
WO2000056709A1 (en) 1999-03-24 2000-09-28 Sugen, Inc. Indolinone compounds as kinase inhibitors
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
JP2003535847A (ja) 2000-06-02 2003-12-02 スージェン・インコーポレーテッド 蛋白質キナーゼ／ホスファターゼ阻害剤としてのインドリノン誘導体
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
KR20050004214A (ko) 2002-05-31 2005-01-12 에자이 가부시키가이샤 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물
US7148249B2 (en) 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
WO2004037247A1 (en) * 2002-10-21 2004-05-06 Irm Llc Oxindoles with anti-hiv activity
WO2005058309A1 (en) 2003-12-16 2005-06-30 Leo Pharma A/S Novel therapeutic use of indolinone derivatives
US20050211590A1 (en) 2004-03-26 2005-09-29 Mcclure George K Protective cover for medical devices
DE102005005395A1 (de) 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
US7309787B2 (en) * 2005-07-13 2007-12-18 Allergan, Inc. Kinase inhibitors
WO2007058626A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
US20070135509A1 (en) 2005-12-09 2007-06-14 Blackburn Thomas P Indolone compounds useful to treat cognitive impairment
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2007109026A2 (en) 2006-03-15 2007-09-27 The Trustees Of Columbia University In The City Of New York Pten compositions and methods for detecting breast cancer
GB0606234D0 (en) 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
JP5551066B2 (ja) * 2007-06-12 2014-07-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
NZ584760A (en) 2007-09-25 2012-03-30 Takeda Pharmaceutical Polo-like kinase inhibitors
WO2009065232A1 (en) 2007-11-20 2009-05-28 University Health Network Cancer diagnostic and therapeutic methods that target plk4/sak
US8765748B2 (en) * 2007-12-21 2014-07-01 University Health Network Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
JP2009173629A (ja) * 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体
CN102014900B (zh) * 2008-03-11 2014-04-02 大学健康网络 一种神经肽y5r(npy5r)拮抗剂在制备治疗癌症的药物中的应用
EP2108641A1 (en) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
AU2009271406A1 (en) 2008-06-16 2010-01-21 Tigris Pharmaceuticals, Inc. Methods for determining sensitivity to aminoflavones
DE102008040187A1 (de) 2008-07-04 2010-01-07 Robert Bosch Gmbh Sensorelement, Verfahren zu seiner Herstellung sowie Verwendung
EP2320907A4 (en) 2008-08-05 2012-09-05 Merck Sharp & Dohme THERAPEUTIC COMPOUNDS
ES2465971T3 (es) * 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
WO2011069298A1 (en) * 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
JP5056876B2 (ja) 2010-03-19 2012-10-24 Ｊｆｅスチール株式会社 冷間加工性と焼入れ性に優れた熱延鋼板およびその製造方法
MX2012011516A (es) * 2010-04-06 2013-03-08 Univ Health Network Inhibidores de cinasa, y metodo para tratar el cancer con los mismos.
US8933070B2 (en) 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
WO2012048411A1 (en) 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
CN103476770B (zh) 2010-11-25 2017-02-15 拉蒂欧制药有限责任公司 阿法替尼盐和多晶型物
JP2014511389A (ja) * 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換６，５−縮合二環式ヘテロアリール化合物
GB201109966D0 (en) 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating pten mutated or deficient cancer
US9580390B2 (en) 2011-10-12 2017-02-28 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
JP6492072B2 (ja) 2013-10-18 2019-03-27 ユニバーシティー ヘルス ネットワーク Ｐｌｋ４阻害剤の塩および結晶形態
EA030089B1 (ru) 2013-10-18 2018-06-29 Юниверсити Хелс Нетуорк Лечение рака поджелудочной железы

Also Published As

Publication number Publication date
US20150133677A1 (en) 2015-05-14
EP2556070B1 (en) 2017-06-07
TWI516262B (zh) 2016-01-11
BR112012025496B1 (pt) 2021-02-23
HUE030651T2 (en) 2017-05-29
CN102892766A (zh) 2013-01-23
US20140045838A1 (en) 2014-02-13
US9796703B2 (en) 2017-10-24
ES2603613T3 (es) 2017-02-28
ME02545B (me) 2017-02-20
US8481533B2 (en) 2013-07-09
NZ602350A (en) 2014-05-30
EP2556070A1 (en) 2013-02-13
WO2011123946A1 (en) 2011-10-13
EP2556071A1 (en) 2013-02-13
KR101782668B1 (ko) 2017-09-27
CY1118610T1 (el) 2017-07-12
US9579327B2 (en) 2017-02-28
EP2556071B1 (en) 2016-08-17
JP5442906B2 (ja) 2014-03-19
US9139563B2 (en) 2015-09-22
US20110263598A1 (en) 2011-10-27
WO2011123947A8 (en) 2011-12-22
HRP20161498T1 (hr) 2016-12-16
LT2556071T (lt) 2017-01-25
ES2639757T3 (es) 2017-10-30
US20160045511A1 (en) 2016-02-18
PT2556071T (pt) 2016-11-22
SG183875A1 (en) 2012-10-30
CN102892766B (zh) 2015-05-20
US8921545B2 (en) 2014-12-30
EA201270752A1 (ru) 2013-04-30
US10077255B2 (en) 2018-09-18
KR20130108065A (ko) 2013-10-02
AU2011238384A1 (en) 2012-09-27
US20180282306A1 (en) 2018-10-04
WO2011123947A1 (en) 2011-10-13
IL221556A (en) 2015-04-30
SMT201600430B (it) 2017-01-10
TW201134471A (en) 2011-10-16
US20180105511A1 (en) 2018-04-19
US20170226088A1 (en) 2017-08-10
EA023173B1 (ru) 2016-04-29
US20120264800A1 (en) 2012-10-18
BR112012025496A2 (pt) 2020-08-18
DK2556071T3 (en) 2016-12-12
EP2556070A4 (en) 2013-10-23
PL2556071T3 (pl) 2017-02-28
AU2011238384B2 (en) 2015-02-19
WO2011123946A8 (en) 2011-12-08
EP2556071A4 (en) 2013-09-04
US8263596B2 (en) 2012-09-11
MX2012011516A (es) 2013-03-08
US9907800B2 (en) 2018-03-06
JP2013523784A (ja) 2013-06-17
US10358436B2 (en) 2019-07-23
US20130096301A1 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
LT2556071T (lt) Kinazės inhibitoriai ir jų panaudojimas vėžio gydymui
HRP20171474T1 (hr) Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka
HK1182019A1 (en) Morpholino pyrimidines and their use in therapy
IL225442A0 (en) Preparations containing rankl suppressors and their uses for the prevention and treatment of cancer
HK1203396A1 (en) Inhibitors of notch signalling pathway and use thereof in treatment of cancers notch
IL214626A0 (en) Prodrug forms of kinase inhibitors and their use in therapy
SG11201404596UA (en) Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
EP2417127A4 (en) KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH THE SAME
IL232353B (en) An inhibitor of the nedd8 mecatenase and a hypomethylated agent for use in cancer therapy
IL228847A0 (en) il1r1 inhibitors and their use in cancer treatment
HK1179997A1 (en) Neuregulin antagonists and use thereof in treating cancer
IL218182A0 (en) Kinase inhibitors, prodrug forms thereof and their use in therapy
HK1215672A1 (zh) 用於治療炎症和癌症的吲哚類化合物
EP2744786A4 (en) SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER
EP2533806A4 (en) METHODS AND MATERIALS FOR TREATING CANCER
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
RS55471B1 (sr) Inhibitori kinaze i njihova upotreba za lečenje kancera
ZA201105917B (en) Prodrug forms of kinase inhibitors and their use in therapy